Ragnar Hultborn

Intraperitoneal alpha-Emitting Radioimmunotherapy with At-211 in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
Andreas Hallqvist, Karin Bergmark, Tom Bäck, Håkan Andersson, Pernilla Dahm-Kähler et al.
Journal of Nuclear Medicine, Journal article 2019
Journal article

Radiosensitivity: Gender and Order of Administration of G-CSF, An Experimental Study in Mice
Ragnar Hultborn, Per Albertsson, Susanne Ottosson, Elisabet Warnhammar, Åsa Palm et al.
Radiation Research, Journal article 2019
Journal article

Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes.
Stig Palm, Tom Bäck, Sture Lindegren, Ragnar Hultborn, Lars Jacobsson et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Journal article 2018
Journal article

Blood flow, volume and arterio-venous passages in induced mammary tumours of the rat
Ragnar Hultborn
Microvascular Research, Journal article 2018
Journal article

Accelerated or conventional whole brain irradiation of malignant melanoma.
Ragnar Hultborn, Johanna Sand, Sara Kinhult, Lotta Lundgren, Ulrika Stierner et al.
Acta oncologica (Stockholm, Sweden), Journal article 2017
Journal article

Therapeutic efficacy of alpha-radioimmunotherapy with different activity levels of the Bi-213-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, Ragnar Hultborn, Stig Palm et al.
EJNMMI Research, Journal article 2017
Journal article

Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity
Jonas Högberg, Magnus Rizell, Ragnar Hultborn, Johanna Svensson, Olof Henrikson et al.
EJNMMI Physics, Journal article 2015
Journal article

IVIM reveals increased blood perfusion of liver metastases after oral intake of Salovum®
Mikael Montelius, Oscar Gustafsson, Mats Andersson, Eva Forssell-Aronsson, Ragnar Hultborn et al.
Magnetic Resonance Materials in Physics, Biology and Medicine. ESMRMB 2015, 32nd Annual Scientific Meeting, Edinburgh, UK, 1-3 October, Conference contribution 2015
Conference contribution

Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
Elin Cederkrantz, Håkan Andersson, Peter Bernhardt, Thomas Backhaus, Ragnar Hultborn et al.
International journal of radiation oncology, biology, physics, Journal article 2015
Journal article

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
Sture Lindegren, Luciana N S Andrade, Tom Bäck, Camila Maria L Machado, Bruno Brasil Horta et al.
PloS one, Journal article 2015
Journal article

Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, Ingela Claesson, Ragnar Hultborn et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Journal article 2006
Journal article

Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, Ingela Claesson, Ragnar Hultborn et al.
Nucl Med Biol, Journal article 2006
Journal article

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
K. Villman, J. Sjostrom, R. Heikkila, Ragnar Hultborn, P. Malmstrom et al.
Acta Oncol, Journal article 2006
Journal article

Early disturbance of microvascular function precedes chemotherapy-induced intestinal injury
Edvard Abel, Tor Ekman, Elisabet Warnhammar Finnborg, Ragnar Hultborn, Eva Jennische et al.
Dig Dis Sci, Journal article 2005
Journal article

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, Ragnar Hultborn, H. Jensen et al.
J Nucl Med, Journal article 2005
Journal article

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo
Tom Bäck, Håkan Andersson, C. R. Divgi, Ragnar Hultborn, H. Jensen et al.
J Nucl Med, Journal article 2005
Journal article

Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice
Jörgen Elgqvist, Peter Bernhardt, Ragnar Hultborn, H. Jensen, Börje Karlsson et al.
J Nucl Med, Journal article 2005
Journal article

Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group
B. Glimelius, O. Dahl, B. Cedermark, A. Jakobsen, S. M. Bentzen et al.
Acta Oncol, Journal article 2005
Journal article

Existential pain--an entity, a provocation, or a challenge?
P. Strang, Susann Strang, Ragnar Hultborn, S. Arner
J Pain Symptom Manage, Journal article 2004
Journal article

Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
Håkan Andersson, Jörgen Elgqvist, György Horvath, Ragnar Hultborn, Lars Jacobsson et al.
Clin Cancer Res, Journal article 2003
Journal article